Patentability, Biosimilars Top Life Sciences Issues for 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.

January 13, 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

Related Publications

June 21, 2022
Briefly: How To Oppose An Extension If You Really Need To
Lauren J. Coppola and Rebecca Bact - Minnesota Lawyer
June 7, 2022
Damned if You Do,
Damned if You Don’t
Taylore Karpa Schollard - The Robins Kaplan Insurance Insight
June 7, 2022
Take-Home COVID: The New Frontier?
Erica Ramsey - The Robins Kaplan Insurance Insight
June 7, 2022
What’s in a Name?
Michele N. Detherage, Esq. - The Robins Kaplan Insurance Insight
June 7, 2022
Women Leaders Excel
In Times of Crisis:
Melissa D'Alelio - The Robins Kaplan Insurance Insight
Back to Top